190 related articles for article (PubMed ID: 38702996)
41. Immuno-Oncology: Emerging Targets and Combination Therapies.
Marshall HT; Djamgoz MBA
Front Oncol; 2018; 8():315. PubMed ID: 30191140
[TBL] [Abstract][Full Text] [Related]
42. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Khair DO; Bax HJ; Mele S; Crescioli S; Pellizzari G; Khiabany A; Nakamura M; Harris RJ; French E; Hoffmann RM; Williams IP; Cheung A; Thair B; Beales CT; Touizer E; Signell AW; Tasnova NL; Spicer JF; Josephs DH; Geh JL; MacKenzie Ross A; Healy C; Papa S; Lacy KE; Karagiannis SN
Front Immunol; 2019; 10():453. PubMed ID: 30941125
[TBL] [Abstract][Full Text] [Related]
43. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
[TBL] [Abstract][Full Text] [Related]
44. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.
Quagliariello V; Passariello M; Bisceglia I; Paccone A; Inno A; Maurea C; Rapuano Lembo R; Manna L; Iovine M; Canale ML; Scherillo M; Ascierto PA; Gabrielli D; De Lorenzo C; Maurea N
Front Cardiovasc Med; 2024; 11():1232269. PubMed ID: 38322766
[TBL] [Abstract][Full Text] [Related]
45. LAG-3: from molecular functions to clinical applications.
Maruhashi T; Sugiura D; Okazaki IM; Okazaki T
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929051
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
47. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
48. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor.
Chocarro L; Bocanegra A; Blanco E; Fernández-Rubio L; Arasanz H; Echaide M; Garnica M; Ramos P; Piñeiro-Hermida S; Vera R; Escors D; Kochan G
Cells; 2022 Jul; 11(15):. PubMed ID: 35954196
[TBL] [Abstract][Full Text] [Related]
49. LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.
Sordo-Bahamonde C; Lorenzo-Herrero S; González-Rodríguez AP; Payer ÁR; González-García E; López-Soto A; Gonzalez S
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925565
[TBL] [Abstract][Full Text] [Related]
50. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands.
Kamali AN; Bautista JM; Eisenhut M; Hamedifar H
Ther Adv Vaccines Immunother; 2023; 11():25151355231192043. PubMed ID: 37662491
[TBL] [Abstract][Full Text] [Related]
51. The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
Lecocq Q; Keyaerts M; Devoogdt N; Breckpot K
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374804
[TBL] [Abstract][Full Text] [Related]
52. LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors.
Sauer N; Szlasa W; Jonderko L; Oślizło M; Kunachowicz D; Kulbacka J; Karłowicz-Bodalska K
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077354
[TBL] [Abstract][Full Text] [Related]
53. A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.
Manna L; Rapuano Lembo R; Yoshioka A; Nakamura K; Passariello M; De Lorenzo C
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001604
[TBL] [Abstract][Full Text] [Related]
54. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
55. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
56. Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.
Amir Taghavi B; Alizadeh N; Saeedi H; Karim Ahangar N; Derakhshani A; Hajiasgharzadeh K; Silvestris N; Baradaran B; Brunetti O
Molecules; 2022 May; 27(11):. PubMed ID: 35684481
[TBL] [Abstract][Full Text] [Related]
57. PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.
Stecher C; Battin C; Leitner J; Zettl M; Grabmeier-Pfistershammer K; Höller C; Zlabinger GJ; Steinberger P
Front Immunol; 2017; 8():572. PubMed ID: 28588576
[TBL] [Abstract][Full Text] [Related]
58. Novel targets for immune-checkpoint inhibition in cancer.
Borgeaud M; Sandoval J; Obeid M; Banna G; Michielin O; Addeo A; Friedlaender A
Cancer Treat Rev; 2023 Nov; 120():102614. PubMed ID: 37603905
[TBL] [Abstract][Full Text] [Related]
59. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
60. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]